title: [A new long-acting Partusisten preparation for oral tocolysis--results of a multicenter study].
abstract: The new 14 mg Partusisten Depot Perlonget from Boehringer Ingelheim was tested in a multi-centre study for its uterine relaxant effect and duration of action, tolerance and the main side-effects over a period of 72 hours under the usual clinical conditions in 64 female patients with premature labour in the 29-36th week of pregnancy. The uterine activity which had increased owing to the premature labour and which was clearly reduced with i.v. infusion of Partusisten was still inhibited on the following 3 days under treatment with Partusisten Depot Perlongets. There was no increase in the rate or intensity of labour at the end of the 8-hour interval between doses of the Perlongets. The uterine relaxant effect and tolerance were good in 69% to 84% of cases. Side-effects were limited to restlessness, tremor and cardiovascular complaints which subsided clearly in the course of treatment. The average heart rate of the patients which was elevated at the start of treatment tended to normal range during treatment with Partusisten Depot Perlongets. The foetal heart rate remained normal. Thus the effect of Partusisten Depot Perlongets with 14 mg lasted for 8 hours, they are highly effective and particularly well tolerated.
mesh_terms: D000284:Administration, Oral; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D014590:Uterine Contraction / Q000187:drug effects
chemical_list: D003692:Delayed-Action Preparations; D004983:Ethanolamines; D005280:Fenoterol
vernacular_title: Ein neues, langwirkendes Partusisten-Präparat zur oralen Tokolyse--Ergebnisse einer multizentrischen Studie.